Thursday 6-12-2014 Halozyme Therapeutics (HALO) $HALO opened at 9.67 hitting the high price of 10.33 and a day low of 9.58 with a total volume of 4,338,927. HALO had a previous close of 9.39 and has been seeing an average volume of 1,943,250.
Overall Average: 48% Buy
Recent stock forum discussions about HALO http://investorshangout.com/search?q=HALO&...mp;yt0=Go!
Why Halozyme Therapeutics Inc. Shares Surged
Sean Williams, The Motley Fool - Motley Fool - Thu Jun 12, 1:34PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Halozyme Therapeutics , a developer of... (full story)
Nasdaq stocks posting largest percentage increases
AP - Thu Jun 12, 12:19PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.: (full story)
Upgrade Alert for Halozyme Therapeutics (HALO)
Comtex SmarTrend(R) - Thu Jun 12, 7:01AM CDT
Halozyme Therapeutics (NASDAQ:HALO) was upgraded from Neutral to Buy at UBS today. The stock closed yesterday at $9.39 on volume of 1.6 million shares, below average daily volume of 2.2 million. Over the past year, Halozyme Therapeutics has traded in a range of $3.86 to $18.18 and closed yesterday at $9.39, 143% above that low. The 200-day and 50-day moving averages have moved 0.25% higher and 2.2% lower over the past week, respectively. (full story)
Why Halozyme Therapeutics Was Upgraded To 'Buy' This Morning
at The Street - Thu Jun 12, 7:01AM CDT
About Halozyme Therapeutics, UBS:said 'We like the positioning from here. Upgrading...on pipeline potential and risk/reward.' (full story)
Biotech Stock Roundup: Biogen Hemophilia Drug Approved, Ariad & Halozyme Clinical Hold Lifted - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 11, 11:16AM CDT
The week so far has been highly eventful (full story)
3 Stocks Under $10 to Trade for Breakouts
at The Street - Wed Jun 11, 5:00AM CDT
These under-$10 stocks are within range of triggering breakout trades. (full story)
This Week in Biotech: A Trifecta of Disappointment Mars ASCO While Biogen Scores a Big Victory
Sean Williams, The Motley Fool - Motley Fool - Sat Jun 07, 12:05PM CDT
With the SPDR S&P Biotech Index up 25% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and... (full story)
Biotech Equities under the Scanner -- Research on Halozyme Therapeutics, Medivation, Achillion Pharma, and Alexion Pharma
PR Newswire - Fri Jun 06, 7:10AM CDT
On Thursday, June 05, 2014, the NASDAQ Composite ended at 4,296.23, up 1.05%, the Dow Jones Industrial Average finished the day 0.59% higher at 16,836.11, and the S&P 500 closed at 1,940.46, up 0.65%. The gains were broad based as all the ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 695.40, up 0.16%, and the index has advanced 3.39% in the last one month. Investor-Edge has initiated coverage on the following equities: Halozyme Therapeutics Inc. (NASDAQ: HALO), Medivation Inc. (NASDAQ: MDVN), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN) and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). Free technical research on HALO, MDVN, ACHN and ALXN can be downloaded upon signing up at: (full story)
Halozyme Study Clinical Hold Lifted by FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 05, 5:26PM CDT
Halozyme Therapeutics, Inc. (HALO) announced that the FDA has removed the clinical hold from PEGPH20 phase II study (Study 202) for stage IV metastatic pancreatic cancer. (full story)
Up 12%: Halozyme Therapeutics Is Back to Work
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu Jun 05, 4:53PM CDT
Halozyme Therapeutics investors had a great day today, with the stock up 12% on the news that the FDA lifted a clinical hold on its phase 2 trial of PEGPH20 for pancreatic cancer. The hold had reflected FDA concerns about potential blood clots,... (full story)
Why Bio-Reference Laboratories, Ciena, and Halozyme Therapeutics Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu Jun 05, 4:15PM CDT
Not to sound like a broken record, but today's economic data was, again, less than exciting, yet the broad-based S&P 500 scorched short-sellers by surging to another fresh all-time closing high. The big news event of the day was the... (full story)
GM and Rite Aid are big market movers
AP - Thu Jun 05, 3:31PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market: (full story)
Why Halozyme Therapeutics Inc. Shares Soared
Sean Williams, The Motley Fool - Motley Fool - Thu Jun 05, 2:24PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Halozyme Therapeutics , a... (full story)
Why Halozyme Therapeutics (HALO) Stock Is Spiking Today
at The Street - Thu Jun 05, 10:25AM CDT
Halozyme Therapeutics (HALO) shares are up after it was given the green light to continue its pancreatic cancer drug trials. (full story)
Today's Top Biotech Stocks to Watch: Halozyme Therapeutics, Inc. and Novavax, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Jun 05, 8:09AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Halozyme and Novavax Halozyme shares are up over 13% in premarket this morning following the announcement that the clinical hold on the company's... (full story)
Ahead of the Bell: Halozyme Therapeutics soars
By The Associated Press - AP - Thu Jun 05, 7:07AM CDT
Halozyme Therapeutics shares jumped more than 13 percent in premarket trading Thursday after the drug developer said regulators have lifted a hold on a clinical study of its possible pancreatic cancer treatment. (full story)
Why Halozyme Therapeutics Is Soaring in After-Hours Trading Today
at The Street - Wed Jun 04, 3:31PM CDT
Halozyme Therapeutics (HALO) surged in after-hours trading after the biopharmaceutical company announced it would resume its PEGPH20 clinical trial. (full story)
Halozyme To Resume PEGPH20 Clinical Program In Pancreatic Cancer
PR Newswire - Wed Jun 04, 3:05PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on patient enrollment and dosing of PEGPH20 in the ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer permitting the study to resume under a revised protocol. Patient enrollment is anticipated to recommence upon review and approval of the amended protocol by the Independent Review Boards at the participating clinical trial sites. In May, the trial's independent Data Monitoring Committee (DMC) recommended that enrollment and dosing in the study resume under a revised protocol. (full story)
Downtrend Call Working As Halozyme Therapeutics Stock Falls 43.1% (HALO)
Comtex SmarTrend(R) - Wed Jun 04, 9:36AM CDT
SmarTrend identified a Downtrend for Halozyme Therapeutics (NASDAQ:HALO) on March 13th, 2014 at $13.63. In approximately 3 months, Halozyme Therapeutics has returned 43.14% as of today's recent price of $7.75. (full story)
Halozyme Therapeutics To Present At The Jefferies 2014 Global Health Care Conference
PR Newswire - Thu May 29, 3:30PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Jefferies 2014 Global Health Care Conference in New York, NY, on Thursday, June 5, 2014 at 12:30 p.m. ET/9:30 a.m. PT. Dr. Helen Torley, Chief Executive Officer, will provide a corporate overview. (full story)
Overall Average: 48% Buy
Recent stock forum discussions about HALO http://investorshangout.com/search?q=HALO&...mp;yt0=Go!
Why Halozyme Therapeutics Inc. Shares Surged
Sean Williams, The Motley Fool - Motley Fool - Thu Jun 12, 1:34PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Halozyme Therapeutics , a developer of... (full story)
Nasdaq stocks posting largest percentage increases
AP - Thu Jun 12, 12:19PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.: (full story)
Upgrade Alert for Halozyme Therapeutics (HALO)
Comtex SmarTrend(R) - Thu Jun 12, 7:01AM CDT
Halozyme Therapeutics (NASDAQ:HALO) was upgraded from Neutral to Buy at UBS today. The stock closed yesterday at $9.39 on volume of 1.6 million shares, below average daily volume of 2.2 million. Over the past year, Halozyme Therapeutics has traded in a range of $3.86 to $18.18 and closed yesterday at $9.39, 143% above that low. The 200-day and 50-day moving averages have moved 0.25% higher and 2.2% lower over the past week, respectively. (full story)
Why Halozyme Therapeutics Was Upgraded To 'Buy' This Morning
at The Street - Thu Jun 12, 7:01AM CDT
About Halozyme Therapeutics, UBS:said 'We like the positioning from here. Upgrading...on pipeline potential and risk/reward.' (full story)
Biotech Stock Roundup: Biogen Hemophilia Drug Approved, Ariad & Halozyme Clinical Hold Lifted - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 11, 11:16AM CDT
The week so far has been highly eventful (full story)
3 Stocks Under $10 to Trade for Breakouts
at The Street - Wed Jun 11, 5:00AM CDT
These under-$10 stocks are within range of triggering breakout trades. (full story)
This Week in Biotech: A Trifecta of Disappointment Mars ASCO While Biogen Scores a Big Victory
Sean Williams, The Motley Fool - Motley Fool - Sat Jun 07, 12:05PM CDT
With the SPDR S&P Biotech Index up 25% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and... (full story)
Biotech Equities under the Scanner -- Research on Halozyme Therapeutics, Medivation, Achillion Pharma, and Alexion Pharma
PR Newswire - Fri Jun 06, 7:10AM CDT
On Thursday, June 05, 2014, the NASDAQ Composite ended at 4,296.23, up 1.05%, the Dow Jones Industrial Average finished the day 0.59% higher at 16,836.11, and the S&P 500 closed at 1,940.46, up 0.65%. The gains were broad based as all the ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 695.40, up 0.16%, and the index has advanced 3.39% in the last one month. Investor-Edge has initiated coverage on the following equities: Halozyme Therapeutics Inc. (NASDAQ: HALO), Medivation Inc. (NASDAQ: MDVN), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN) and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). Free technical research on HALO, MDVN, ACHN and ALXN can be downloaded upon signing up at: (full story)
Halozyme Study Clinical Hold Lifted by FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 05, 5:26PM CDT
Halozyme Therapeutics, Inc. (HALO) announced that the FDA has removed the clinical hold from PEGPH20 phase II study (Study 202) for stage IV metastatic pancreatic cancer. (full story)
Up 12%: Halozyme Therapeutics Is Back to Work
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu Jun 05, 4:53PM CDT
Halozyme Therapeutics investors had a great day today, with the stock up 12% on the news that the FDA lifted a clinical hold on its phase 2 trial of PEGPH20 for pancreatic cancer. The hold had reflected FDA concerns about potential blood clots,... (full story)
Why Bio-Reference Laboratories, Ciena, and Halozyme Therapeutics Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu Jun 05, 4:15PM CDT
Not to sound like a broken record, but today's economic data was, again, less than exciting, yet the broad-based S&P 500 scorched short-sellers by surging to another fresh all-time closing high. The big news event of the day was the... (full story)
GM and Rite Aid are big market movers
AP - Thu Jun 05, 3:31PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market: (full story)
Why Halozyme Therapeutics Inc. Shares Soared
Sean Williams, The Motley Fool - Motley Fool - Thu Jun 05, 2:24PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Halozyme Therapeutics , a... (full story)
Why Halozyme Therapeutics (HALO) Stock Is Spiking Today
at The Street - Thu Jun 05, 10:25AM CDT
Halozyme Therapeutics (HALO) shares are up after it was given the green light to continue its pancreatic cancer drug trials. (full story)
Today's Top Biotech Stocks to Watch: Halozyme Therapeutics, Inc. and Novavax, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Jun 05, 8:09AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Halozyme and Novavax Halozyme shares are up over 13% in premarket this morning following the announcement that the clinical hold on the company's... (full story)
Ahead of the Bell: Halozyme Therapeutics soars
By The Associated Press - AP - Thu Jun 05, 7:07AM CDT
Halozyme Therapeutics shares jumped more than 13 percent in premarket trading Thursday after the drug developer said regulators have lifted a hold on a clinical study of its possible pancreatic cancer treatment. (full story)
Why Halozyme Therapeutics Is Soaring in After-Hours Trading Today
at The Street - Wed Jun 04, 3:31PM CDT
Halozyme Therapeutics (HALO) surged in after-hours trading after the biopharmaceutical company announced it would resume its PEGPH20 clinical trial. (full story)
Halozyme To Resume PEGPH20 Clinical Program In Pancreatic Cancer
PR Newswire - Wed Jun 04, 3:05PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on patient enrollment and dosing of PEGPH20 in the ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer permitting the study to resume under a revised protocol. Patient enrollment is anticipated to recommence upon review and approval of the amended protocol by the Independent Review Boards at the participating clinical trial sites. In May, the trial's independent Data Monitoring Committee (DMC) recommended that enrollment and dosing in the study resume under a revised protocol. (full story)
Downtrend Call Working As Halozyme Therapeutics Stock Falls 43.1% (HALO)
Comtex SmarTrend(R) - Wed Jun 04, 9:36AM CDT
SmarTrend identified a Downtrend for Halozyme Therapeutics (NASDAQ:HALO) on March 13th, 2014 at $13.63. In approximately 3 months, Halozyme Therapeutics has returned 43.14% as of today's recent price of $7.75. (full story)
Halozyme Therapeutics To Present At The Jefferies 2014 Global Health Care Conference
PR Newswire - Thu May 29, 3:30PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Jefferies 2014 Global Health Care Conference in New York, NY, on Thursday, June 5, 2014 at 12:30 p.m. ET/9:30 a.m. PT. Dr. Helen Torley, Chief Executive Officer, will provide a corporate overview. (full story)
